Cochrane Abstracts
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer New
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437748/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer_New. Accessed 04 July 2022.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437748/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer_New. Accessed July 4, 2022.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/437748/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer_New
Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer New [Internet]. In: Cochrane Abstracts. [cited 2022 July 04]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437748/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer New
ID - 437748
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437748/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer_New
DB - Evidence Central
DP - Unbound Medicine
ER -
